Mesothelioma is a terrible condition, diagnosis can be difficult and for many it comes too when their condition is more advanced and many treatment options are no longer suitable.
A new blood test for malignant mesothelioma is on the horizon. Using a calcium-binding protein called calretinin, which governs a number of critical cellular processes, researchers tested against an already established mesothelioma biomarker, mesothelin.
The study looked at samples of blood serum and plasma from nearly 200 men with malignant pleural mesothelioma, against more than 200 men with non-malignant asbestos related conditions such as asbestosis or pleural plaques.
The results found that in 71% of the samples the calretinin based test correctly identified cases of epitheloid or biphasic mesothelioma whereas the mesothelin based test was only correct 69% of the time. However, when both tests were used together, the calretinin increased the sensitivity of the mesothelioma and the test was correct 75% of the time.
The only time the calretinin test was not as effective was when trying to identify sarcomatoid mesothelioma, this is the rarest type of the asbestos related cancer.
Any method to try and diagnose mesothelioma more effectively and efficiently is good news. A swift diagnosis gives patients more treatment options and can help provide a better quality of life.
If you require assistance in pursuing an asbestos compensation claim for mesothelioma or other asbestos disease then please contact us today on our freephone number 0800 038 6767. Alternatively, head over to the ‘Contact Us’ page, complete the form and we will be in touch.
Johnen, G, et al, “Calretinin as a blood-based biomarker for mesothelioma”, May 30, 2017, BMC Cancer,